Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration

Experimental Neurology

Volumn 223, Issue 2, 2010, Pages 657-661

  Kachroo, Anil ^a   Irizarry, Michael C ^a,b   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Caffeine; Mouse; Parkinson's disease; Pesticide; Stereology; Striatum; Substantia nigra

Indexed keywords

CAFFEINE; MANEB; PARAQUAT; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; LONG TERM EXPOSURE; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; CAFFEINE; CELL COUNT; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG INTERACTIONS; FUNGICIDES, INDUSTRIAL; HERBICIDES; LOCOMOTION; MALE; MANEB; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARAQUAT; SUBSTANTIA NIGRA;

EID: 77952545692     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.02.007     Document Type: Article

References (49)

1. Aguiar L.M.V., Nobre H.V., Macedo D.S., Oliveira A.A., Freitas R.M., Vasconcelos S.M., Cunha G.M.A., Sousa F.C.F., Viana G.S.B. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesions in rats. Pharmacol. Biochem. Behav. 2006, 84(3):415-419.
2. Anderson D.W., Bradbury K.A., Schneider J.S. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur. J. NeuroSci. 2006, 24:3174-3182.
3. Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50:56-63.
4. Ascherio A., Chen H., Weisskopf M.G., O'Reilly E., McCullough M.L., Calle E.E., Schwarzschild M.A., Thun M.J. Pesticide exposure and risk for Parkinson's disease. Ann. Neurol. 2006, 60:197-203.
5. Aumann T.D., Gantois I., Egan K., Vais A., Tomas D., Drago J., Horne M.K. SK channel function regulates the dopamine phenotype of neurons in the substantia nigra pars compacta. Exp. Neurol. 2008, 213:419-430.
6. Baldi I., Lebailly P., Mohammed-Brahim B., Letenneur L., Dartigues J.F., Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am. J. Epidemiol. 2003, 157:409-414.
7. 2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp. Brain Res. 2005, 165(3):362-374.
8. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 1999, 823:1-10.
9. 2A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2009, 111:1478-1489.
10. Cavalieri B. Geometria degli indivisibili 1966, Unione Tipografico. Editrice, Torino, Italy.
11. Chade A.R., Kasten M., Tanner C.M. Non genetic causes of Parkinson's disease. J. Neural. Transm. Suppl. 2006, 70:147-151.
12. Chan P., Dimonte D.A., Langston J.W., Janson A.M. (+) MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J. Pharmacol. Exp. Ther. 1997, 280:439-446.
13. Chen J.-F., Xu K., Petzer J.P., Staal R., Xu Y.-H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N., Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001, 21(RC143):1-6.
14. Costello S., Cockburn M., Bronstein J., Zhang X., Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am. J. Epidemiol. 2009, 169:919-926.
15. Datta U., Noailess A.H.P., Rodriguez M., Kraft M., Zhang Y. Accumulation of tyrosine hydroxylase messenger RNA molecules in the rat mesencephalon by chronic caffeine treatment. Neurosci. Lett. 1996, 230:77-80.
16. Ferraz H.B., Bertolucci P.H.F., Pereira J.S., Lima J.G.C., Andrade L.A.F. Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. Neurology 1988, 38:550-553.
17. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti G.L., Pontarelli F., Battaglia G., Pelligrini A., Nicoletti F., Ruggieri S., Paparelli A., Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3413-3418.
18. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 1991, 257(2):691-697.
19. Heikkila R.E. Differential neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur. J. Pharmacol. 1985, 117:131-133.
20. Hertzman C., Wiens M., Bowering D., Snow B., Caine D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 1990, 17:349-355.
21. Hung A.Y., Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?. Curr. Opin. Neurol. 2007, 20:477-483.
22. 2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 2002, 80:262-270.
23. Joghataie M.T., Roghani M., Negahdar F., Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat. Disord. 2004, 10(8):465-468.
24. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., Chen R.C. Environmental risk factors and Parkinson's disease: a case control study in Taiwan. Neurology 1997, 48:1583-1588.
25. McCarthy S., Somayajulu M., Sikorska M., Borowy-Borowski H., Pandey S. Paraquat induces oxidative stress and neuronal cell death: neuroprotection by water-soluble coenzyme Q10. Toxicol. Appl. Pharmacol. 2004, 201(1):21-31.
26. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., DiMonte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 2002, 10:119-127.
27. Meco G., Bonifati V., Vanacore N., Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bisdithiocarbamate. Scand. J. Work Environ. Health 1994, 20:301-305.
28. Melvin N.R., Sutherland R.J. Quantitative caveats of standard immunohistochemical procedures: implications for optical disector-based designs. J. Histochem. Cytochem. 2009, 10:1-28.
29. Mizuno Y., Shimoda-Matsubayashi S., Matsumine H., Morikawa N., Hattori N., Kondo T. Genetic and environmental factors in the pathogenesis of Parkinson's disease. Adv. Neurol. 1999, 80:171-179.
30. Oztas E., Kalda A., Xu K., Irizarry M.C., Schwarzschild M.A., Chen J.F. Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice. Soc. Neurosci. 2002, Annual Meeting. Orlando, FL. Abstract # A487.6.
31. Petrovitch H., Ross G.W., Abbott R., Sanderson W.T., Sharp D.S., Tanner C.M., Masaki K.H., Blanchette P.L., Popper J.S., Foley D., Launer L., White L.R. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch. Neurol. 2002, 59:1787-1792.
32. Pierri M., Vaudano E., Sager T., Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005, 48:517-524.
33. 2A receptor stimulation enhances striatal extracellular glutamate levels in the rat striatum. Eur. J. Pharmacol. 1995, 287:215-217.
34. Prasad K., Winnik B., Thiruchelvam M.J., Buckley B., Mirochnitchenko O., Richfield E.K. Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environ. Health Perspect. 2007, 115(10):1448-1453.
35. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003, 60:1234-1240.
36. Saint-Pierre M., Tremblay M.E., Sik A., Gross R.E., Cicchetti F. Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats. J. Neurochem. 2006, 98:760-772.
37. Satomi Y., Tsuchiya W., Mihara K., Ota M., Kasahara Y., Akahori F. Gene expression of the lung following paraquat administration in rats using DNA microarray. J. Toxicol. Sci. 2004, 29:91-100.
38. Suchowersky O., Gronseth G., Perlmutter J., Reich S., Zesiewicz T., Weiner W.J. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:976-982. Quality Standards Subcommittee of the American Academy of Neurology.
39. Tanner C.M., Ross G.W., Jewell S.A., Hauser R.A., Jankovic J., Factor S.A., Bressman S.A., Deligtisch A., Marras C., Lyons K.E., Bhudhikanok G.S., Roucoux D.F., Meng C., Abbott R.D., Langston J.W. Occupation and risk of parkinsonism: a multicenter case control study. Arch. Neurol. 2009, 66(9):1106-1113.
40. Tanner C.M., Chen W.Z., Wang M.L., Peng Z.L., Liu X., Liang L.C., Kao D.W., Gilley D.W., Schoenberg B.S. Environmental factors in the etiology of Parkinson's disease. Can. J. Neurol. Sci. 1987, 14:419-423.
41. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., Cory-Slechta D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res. 2000, 873(2):225-234.
42. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank W.A., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 2000, 20(24):9207-9214.
43. United States Geographic Service Pesticide National Synthesis Project 1998, USGS, Washington, DC.
44. Warner T.T., Schapira A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 2003, 53(Suppl 3S):16-23. discussion S23-5.
45. West M., Slomianka L., Gundersen H.J.G. Unbiased stereological estimation of the total number of neurons in the subdivision of the rat hippocampus using the optical fractionators. Anat. Record 1993, 231:482-497.
46. Wirdefeldt K., Gatz M., Schalling M., Pedersen N.L. No evidence for heritability of Parkinson's disease in Swedish twins. Neurology 2004, 63:305-311.
47. Xu K., Bastia E., Schwarzschild M.A. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2005, 105:267-310.
48. 2A receptor. Soc. Neurosci. 2006, Annual Meeting. Abstract # 470.17.
49. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 2008, 63:338-346.